Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-cell Therapy Plus Nivolumab, Relatlimab, and Ipilimumab in Advanced Ovarian and Related Cancers
2020-002738-34Phase 2Terminated
- Sponsor
- National Center for Cancer Immune Therapy
- Start
- Jul 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous tumor-infiltrating lymphocytes, nivolumab, relatlimab, ipilimumab, cyclophosphamide and 1 more in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by National Center for Cancer Immune Therapy. Primary endpoints: Toxicity and Feasibility. Started Jul 2020; status: terminated.
02
Drugs
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2020-002738-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002738-34.